NEW YORK – A new study published in Science Translational Medicine this week found that MEK inhibitors in combination with BET inhibitors could be potent against high MYCN-expressing triple negative breast cancer.
The authors of the study hope that their findings will accelerate development of BET inhibitors for TNBC, where there is an unmet need.